Josh Bilenker's guest appearances

Josh Bilenker

Twenty Summers

Innovation Files: Where Tech Meets Public Policy

Ben Horowitz

Mike Flanagan

Dan Scheinman

Jacqueline Woodson

Isaac Mizrahi

Damon Young

Pedro Domingos

Kris Delmhorst

Andrew Sullivan

Adam Gopnik

Rion Amilcar Scott

Claudia Rankine

Junot Diaz

Rebecca Makkai

Jodi Kantor

OwlTail

America leads in biopharmaceutical innovation and drug development, in large part due to effective life-science policies, including significant federal investment in basic research, robust intellectual property protections, effective technology transfer policies, investment incentives, and, importantly, drug pricing policies that enable companies to invest in high-risk drug development. Rob and Jackie talk about conducive environments for biopharmaceutical startups—and what the federal government can do to maintain U.S. competitiveness—with Josh Bilenker, CEO of Loxo Oncology at Lilly. Mentioned:Robert D. Atkinson, “Why Life-Sciences Innovation Is Politically “Purple”—and How Partisans Get It Wrong” (ITIF, February 2016). Stephen Ezell, “Ensuring U.S. Biopharmaceutical Competitiveness” (ITIF, July 2020). Related:Stephen Ezell, et al., “The Critical Role of Biopharmaceutical Startups in Driving Life Sciences Innovation,” ITIF webinar, July 16, 2020. Joe Kennedy, “The Link Between Drug Prices and Research on the Next Generation of Cures” (ITIF, September 2019). 

America leads in biopharmaceutical innovation and drug development, in large part due to effective life-science policies, including significant federal investment in basic research, robust intellectual property protections, effective technology transfer policies, investment incentives, and, importantly, drug pricing policies that enable companies to invest in high-risk drug development. Rob and Jackie talk about conducive environments for biopharmaceutical startups—and what the federal government can do to maintain U.S. competitiveness—with Josh Bilenker, CEO of Loxo Oncology at Lilly. Mentioned:<ul><li>Robert D. Atkinson, “<a href="https://itif.org/publications/2016/02/22/why-life-sciences-innovation-politically-purple" rel="nofollow" target="_blank">Why Life-Sciences Innovation Is Politically “Purple”—and How Partisans Get It Wrong</a>” (ITIF, February 2016). </li><li>Stephen Ezell, “<a href="https://itif.org/publications/2020/07/16/ensuring-us-biopharmaceutical-competitiveness" rel="nofollow" target="_blank">Ensuring U.S. Biopharmaceutical Competitiveness</a>” (ITIF, July 2020). </li></ul>Related:<ul><li>Stephen Ezell, et al., “<a href="https://itif.org/events/2020/07/16/critical-role-biopharmaceutical-startups-driving-life-sciences-innovation" rel="nofollow" target="_blank">The Critical Role of Biopharmaceutical Startups in Driving Life Sciences Innovation</a>,” ITIF webinar, July 16, 2020. </li><li>Joe Kennedy, “<a href="https://itif.org/publications/2019/09/09/link-between-drug-prices-and-research-next-generation-cures" rel="nofollow" target="_blank">The Link Between Drug Prices and Research on the Next Generation of Cures</a>” (ITIF, September 2019). </li></ul>

The Risks and Life-Saving Rewards of Biopharmaceutical Investment, With Josh Bilenker

Carl June

David Porter

Immunologist Dr. Carl June, medical oncologist Dr. David Porter, and Loxo Oncology at Lilly CEO Dr. Josh Bilenker gathered virtually early in September to discuss Dr. Porter’s and Dr. June’s groundbreaking immunotherapy work, how work follows them home, and the course of their careers in this lively, moving discussion on what it means to care for those who are running out of hope.Dr. Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research into T cell therapies for the treatment of cancer. In 2020 he was elected to the American Philosophical Society.Dr. David Porter is the Director of Cell Therapy and Transplantation at the Perelman School of Medicine of the University of Pennsylvania. He has been recognized by America’s Top Doctors 2007, 2008, 2010-2018, by Best Doctors in America 2009 - 2018, and Philadelphia magazine’s annual Top Docs issues, 2004 -2020. He is an expert in blood cancer, chronic lymphocytic leukemia (CLL), and leukemia.Dr. Josh Bilenker received his M.D. from The Johns Hopkins School of Medicine and his A.B. from Princeton, awarded summa cum laude in English. Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Dr. Bilenker is CEO of Loxo Oncology at Lilly, serves as a director of Gossamer Bio, and is also a Board Member of the NCCN Foundation and of BioEnterprise.

Immunologist Dr. Carl June, medical oncologist Dr. David Porter, and Loxo Oncology at Lilly CEO Dr. Josh Bilenker gathered virtually early in September to discuss Dr. Porter’s and Dr. June’s groundbreaking immunotherapy work, how work follows them home, and the course of their careers in this lively, moving discussion on what it means to care for those who are running out of hope. Dr. Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research into T cell therapies for the treatment of cancer. In 2020 he was elected to the American Philosophical Society.Dr. David Porter is the Director of Cell Therapy and Transplantation at the Perelman School of Medicine of the University of Pennsylvania. He has been recognized by America’s Top Doctors 2007, 2008, 2010-2018, by Best Doctors in America 2009 - 2018, and Philadelphia magazine’s annual Top Docs issues, 2004 -2020. He is an expert in blood cancer, chronic lymphocytic leukemia (CLL), and leukemia.Dr. Josh Bilenker received his M.D. from The Johns Hopkins School of Medicine and his A.B. from Princeton, awarded summa cum laude in English. Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Dr. Bilenker is CEO of Loxo Oncology at Lilly, serves as a director of Gossamer Bio, and is also a Board Member of the NCCN Foundation and of BioEnterprise.

Healthcare Panel with Doctors Carl June, David Porter & Josh Bilenker